Critical Reviews in Oncology / Hematology
Volume 78, Issue 3 , Pages 220-226 , June 2011

Potential drug interactions in elderly cancer patients

  • V. Girre

      Affiliations

    • Institut Curie, Department of Medical Oncology, 26, rue d’Ulm, 75005 Paris, France
    • On behalf of the POGOP (Programme Onco-Gériatrie de l’Ouest Parisien).
    • Corresponding Author InformationCorresponding author. Tel.: +33 1 44 32 46 88; fax: +33 1 53 10 40 41.
    • ,
  • H. Arkoub

      Affiliations

    • Institut Curie, Department of Medical Oncology, 26, rue d’Ulm, 75005 Paris, France
    • On behalf of the POGOP (Programme Onco-Gériatrie de l’Ouest Parisien).
    • ,
  • M.T.E. Puts

      Affiliations

    • Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Canada
    • On behalf of the POGOP (Programme Onco-Gériatrie de l’Ouest Parisien).
    • ,
  • C. Vantelon

      Affiliations

    • Institut Curie, Department of Medical Oncology, 26, rue d’Ulm, 75005 Paris, France
    • Hôpital Georges Pompidou, Department of Gerontology, Paris, France
    • On behalf of the POGOP (Programme Onco-Gériatrie de l’Ouest Parisien).
    • ,
  • F. Blanchard

      Affiliations

    • University Hospitals of Reims, Department of Clinical Gerontology, Reims, France
    • On behalf of the POGOP (Programme Onco-Gériatrie de l’Ouest Parisien).
    • ,
  • J.P. Droz

      Affiliations

    • Centre Leon Berard, Department of Medical Oncology, Lyon, France
    • On behalf of the POGOP (Programme Onco-Gériatrie de l’Ouest Parisien).
    • ,
  • L. Mignot

      Affiliations

    • Institut Curie, Department of Medical Oncology, 26, rue d’Ulm, 75005 Paris, France
    • On behalf of the POGOP (Programme Onco-Gériatrie de l’Ouest Parisien).

,Accepted 5 May 2010.

References 

  1. Yancik R, Ganz PA, Varricchio CG, Conley B. Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base. J Clin Oncol. 2001;19(February (4)):1147–1151
  2. Jorgensen T, Johansson S, Kennerfalk A, Wallander MA, Svardsudd K. Prescription drug use, diagnoses, and healthcare utilization among the elderly. Ann Pharmacother. 2001;35(September (9)):1004–1009
  3. Legrain S. Prescription to elderly patients: reducing underuse and adverse drug reactions and improving adherence. Bull Acad Natl Med. 2007;191(February (2)):259–269discussion 69–70
  4. Riechelmann RP, Moreira F, Smaletz O, Saad ED. Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol. 2005;56(September (3)):286–290
  5. Sokol KC, Knudsen JF, Li MM. Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management. J Clin Pharm Ther. 2007;32(April (2)):169–175
  6. Girre V, Falcou MC, Gisselbrecht M, et al. Does a geriatric oncology consultation modify the cancer treatment plan for elderly patients?. J Gerontol A: Biol Sci Med Sci. 2008;63(July (7)):724–730
  7. Dergal JM, Gold JL, Laxer DA, et al. Potential interactions between herbal medicines and conventional drug therapies used by older adults attending a memory clinic. Drugs Aging. 2002;19(11):879–886
  8. Spinewine A, Schmader KE, Barber N, et al. Appropriate prescribing in elderly people: how well can it be measured and optimised?. Lancet. 2007;370(July (9582)):173–184
  9. Bouchardy C, Rapiti E, Blagojevic S, Vlastos AT, Vlastos G. Older female cancer patients: importance, causes, and consequences of undertreatment. J Clin Oncol. 2007;25(May (14)):1858–1869
  10. Green JL, Hawley JN, Rask KJ. Is the number of prescribing physicians an independent risk factor for adverse drug events in an elderly outpatient population?. Am J Geriatr Pharmacother. 2007;5(March (1)):31–39
  11. Tamblyn RM, McLeod PJ, Abrahamowicz M, Laprise R. Do too many cooks spoil the broth? Multiple physician involvement in medical management of elderly patients and potentially inappropriate drug combinations. CMAJ. 1996;154(April (8)):1177–1184
  12. McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev. 2004;56(June (2)):163–184
  13. Tulner LR, Kuper IM, Frankfort SV, et al. Discrepancies in reported drug use in geriatric outpatients: relevance to adverse events and drug–drug interactions. Am J Geriatr Pharmacother. 2009;7(April (2)):93–104
  14. Stewart RB, Cooper JW. Polypharmacy in the aged. Practical solutions. Drugs Aging. 1994;4(June (6)):449–461
  15. Bepko RJ, Moore JR, Coleman JR. Implementation of a pharmacy automation system (robotics) to ensure medication safety at Norwalk hospital. Qual Manag Health Care. 2009;18(April–June (2)):103–114
  16. Gurwitz JH, Field TS, Rochon P, et al. Effect of computerized provider order entry with clinical decision support on adverse drug events in the long-term care setting. J Am Geriatr Soc. 2008;56(December (12)):2225–2233
  17. Spinewine A, Swine C, Dhillon S, et al. Effect of a collaborative approach on the quality of prescribing for geriatric inpatients: a randomized, controlled trial. J Am Geriatr Soc. 2007;55(May (5)):658–665
  18. Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch Intern Med. 1991;151(September (9)):1825–1832
  19. Aparasu RR, Mort JR. Inappropriate prescribing for the elderly: beers criteria-based review. Ann Pharmacother. 2000;34(March (3)):338–346
  20. Naugler CT, Brymer C, Stolee P, Arcese ZA. Development and validation of an improving prescribing in the elderly tool. Can J Clin Pharmacol. 2000;7(Summer (2)):103–107
  21. van der Hooft CS, Jong GW, Dieleman JP, et al. Inappropriate drug prescribing in older adults: the updated 2002 Beers criteria – a population-based cohort study. Br J Clin Pharmacol. 2005;60(August (2)):137–144
  22. Gallagher P, O’Mahony D. STOPP (Screening Tool of Older Persons’ potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers’ criteria. Age Ageing. 2008;37(November (6)):673–679
  23. O’Mahony D, Gallagher PF. Inappropriate prescribing in the older population: need for new criteria. Age Ageing. 2008;37(March (2)):138–141
  24. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163(December (22)):2716–2724
  25. Lechevallier-Michel N, Gautier-Bertrand M, Alperovitch A, et al. Frequency and risk factors of potentially inappropriate medication use in a community-dwelling elderly population: results from the 3C Study. Eur J Clin Pharmacol. 2005;60(January (11)):813–819
  26. Blower P, de Wit R, Goodin S, Aapro M. Drug–drug interactions in oncology: why are they important and can they be minimized?. Crit Rev Oncol Hematol. 2005;55(August (2)):117–142
  27. Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007;99(April (8)):592–600
  28. Riechelmann RP, Zimmermann C, Chin SN, et al. Potential drug interactions in cancer patients receiving supportive care exclusively. J Pain Symptom Manage. 2008;35(May (5)):535–543
  29. Bjerrum L, Andersen M, Petersen G, Kragstrup J. Exposure to potential drug interactions in primary health care. Scand J Prim Health Care. 2003;21(September (3)):153–158
  30. Riechelmann RP, Saad ED. A systematic review on drug interactions in oncology. Cancer Invest. 2006;24(November (7)):704–712
  31. Kennerfalk A, Ruigomez A, Wallander MA, Wilhelmsen L, Johansson S. Geriatric drug therapy and healthcare utilization in the United kingdom. Ann Pharmacother. 2002;36(May (5)):797–803
  32. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002;287(January (3)):337–344
  33. Viktil KK, Blix HS, Moger TA, Reikvam A. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol. 2007;63(February (2)):187–195
  34. Rollason V, Vogt N. Reduction of polypharmacy in the elderly: a systematic review of the role of the pharmacist. Drugs Aging. 2003;20(11):817–832
  35. Barat I, Andreasen F, Damsgaard EM. The consumption of drugs by 75-year-old individuals living in their own homes. Eur J Clin Pharmacol. 2000;56(September (6–7)):501–509
  36. Doucet J, Queneau P. Adverse drug reactions in the elderly. Bull Acad Natl Med. 2005;189(November (8)):1693–1707discussion 708–9
  37. Frazier SC. Health outcomes and polypharmacy in elderly individuals: an integrated literature review. J Gerontol Nurs. 2005;31(September (9)):4–11
  38. Shi S, Morike K, Klotz U. The clinical implications of ageing for rational drug therapy. Eur J Clin Pharmacol. 2008;64(February (2)):183–199
  39. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006;296(October (15)):1858–1866
  40. Doucet J, Chassagne P, Trivalle C, et al. Drug–drug interactions related to hospital admissions in older adults: a prospective study of 1000 patients. J Am Geriatr Soc. 1996;44(August (8)):944–948
  41. Puts MT, Costa-Lima B, Monette J, et al. Medication problems in older, newly diagnosed cancer patients in Canada: how Common are they?: a prospective pilot study. Drugs Aging. 2009;26(6):519–536
  42. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc. 1999;47(January (1)):30–39
  43. Herrlinger C, Klotz U. Drug metabolism and drug interactions in the elderly. Best Pract Res Clin Gastroenterol. 2001;15(December (6)):897–918
  44. Aubert RE. Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. J Clin Oncol. 2009;27(18s):abstr CRA 508
  45. Dezentje V. Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: a pharmacoepidemiologic study. J Clin Oncol. 2009;27(18s):abstr CRA 509
  46. Lichtman SM, Boparai MK. Anticancer drug therapy in the older cancer patient: pharmacology and polypharmacy. Curr Treat Options Oncol. 2008;9(June (2–3)):191–203
  47. Tranchand B, Laporte S, Glehen O, Freyer G. Pharmacology of cytotoxic agents: a helpful tool for building dose adjustment guidelines in the elderly. Crit Rev Oncol Hematol. 2003;48(November (2)):199–214
  48. Extermann M, Chen H, Cantor AB, et al. Predictors of tolerance to chemotherapy in older cancer patients: a prospective pilot study. Eur J Cancer. 2002;38(July (11)):1466–1473
  49. Relling MV, Pui CH, Sandlund JT, et al. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet. 2000;356(July (9226)):285–290
  50. Clement JP, Nassif RF, Leger JM, Marchan F. Development and contribution to the validation of a brief French version of the Yesavage Geriatric Depression Scale. Encephale. 1997;23(March–April (2)):91–99

PII: S1040-8428(10)00124-1

doi: 10.1016/j.critrevonc.2010.05.004

Critical Reviews in Oncology / Hematology
Volume 78, Issue 3 , Pages 220-226 , June 2011

Article Tools

* Image Usage & Resolution